Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) thrilled investors with a 412.1% gain last year, according to data from S&P Global Market Intelligence. Positive mid-stage clinical trial results for its lead drug, Resunab, lifted the stock and ignited hope for further expansion in the future.
